Na
Non verificato

Natera, Inc.

Di cosa scriviamo

BiotecnologiaIndustriaMedicina - VarieOncologiaSalute
04/06/2026
Mercato del lavoro
Industria
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Farmaceutica
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
1.00
03/06/2026
Biotecnologia
Salute
Farmaceutica
Oncologia
Mercato del lavoro
Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
1.00
29/05/2026
Mercato del lavoro
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
1.00
28/05/2026
Industria
Scienza
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Sanità
Oncologia
Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer
1.00
26/05/2026
Attrezzature medico-sanitarie
Biotecnologia
Medicina - Varie
Salute
Scienza
Oncologia
Industria
Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology
1.00
21/05/2026
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Eventi
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
1.00
21/05/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Sanità
Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World
1.00
20/05/2026
Industria
Biotecnologia
Assistenza all'Infanzia
Salute
Sanità
Farmaceutica
Oncologia
Vetrine/Shopping
Medicina - Varie
EXPAND Trial of Natera’s Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled
1.00
15/05/2026
Industria
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)
1.00
07/05/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Salute
Oncologia
Natera Reports First Quarter 2026 Financial Results
1.00

Recapiti

Social Media

Seguaci
0
Compatibilità
0